白芍总苷胶囊超说明书治疗口腔黏膜病的用药情况分析

Analysis of the off-label use of total glucosides of white paeony capsules in the treatment of oral mucosal diseases

目的了解白芍总苷胶囊超说明书治疗口腔黏膜病的合理性,为其规范使用提供参考。方法采用回顾性研究方法,对2020年口腔黏膜科1178张白芍总苷胶囊处方中临床诊断、患者性别、患者年龄和药品用法用量进行统计和分析。结果白芍总苷胶囊超说明书适应证用于口腔扁平苔藓(70.88%)、复发性阿弗他溃疡(11.71%)、干燥综合征(7.30%)和盘状红斑狼疮(4.50%)等口腔黏膜病的治疗。处方患者以女性(68.00%)和中老年为主,83.53%处方用法用量符合药品说明书规定。结论白芍总苷胶囊超说明书治疗口腔黏膜病有其使用合理性,医师处方前须取得患者明确知情同意,建议药品生产企业及时完善药品说明书,为医师合理用药及药师开展处方点评提供更多的信息支持。

AIM To understand the rationality of the total glucosides of white paeony capsules in the treatment of oral mucosal diseases so as to provide references for standardizing its use.METHODS Retrospective statistical method was used to analyze the clinical diagnosis,patient gender,patient age,and drug usage and dosage of 1178 total glucosides of white paeony capsule prescriptions in the Department of Oral Medicine in 2020.RESULTS The total glucosides of white paeony capsules were off-label used in the treatment of oral mucosal diseases such as oral lichen planus(70.88%),recurrent aphthous ulcer(11.71%),Sjogren's syndrome(7.30%)and discoid lupus erythematosus(4.50%).The patients were mainly female(68.00%)and middle-aged and elderly,and 83.53%of the prescribed usage and dosage complied with the regulations of drug instruction.CONCLUSION The off-label use of total glucosides of white paeony capsules for the treatment of oral mucosal diseases is reasonable.Doctors must obtain patients'clear and informed consent before prescribing.Drug manufacturer should improve drug instruction in time,so as to provide more information for doctors'rational drug use and pharmacists'prescription comments.